Deepak Mittal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11816572/publications.pdf

Version: 2024-02-01

26 papers 3,194 citations

361045 20 h-index 26 g-index

26 all docs

26 docs citations

times ranked

26

6654 citing authors

#	Article	IF	CITATIONS
1	New insights into cancer immunoediting and its three component phasesâ€"elimination, equilibrium and escape. Current Opinion in Immunology, 2014, 27, 16-25.	2.4	1,163
2	Targeting Cancer-Derived Adenosine: New Therapeutic Approaches. Cancer Discovery, 2014, 4, 879-888.	7.7	256
3	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 2015, 36, 822-846.	4.0	242
4	Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor. Cancer Research, 2014, 74, 3652-3658.	0.4	217
5	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discovery, 2016, 6, 446-459.	7.7	198
6	TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO Journal, 2010, 29, 2242-2252.	3.5	148
7	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. Cancer Research, 2016, 76, 4372-4382.	0.4	130
8	Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis. Cancer Immunology Research, 2017, 5, 1098-1108.	1.6	98
9	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Research, 2017, 77, 5652-5663.	0.4	90
10	NK cells require IL-28R for optimal in vivo activity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2376-84.	3.3	82
11	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. Cancer Immunology Research, 2019, 7, 559-571.	1.6	79
12	Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and antiâ€PDâ€L1 antibody for treatment of tripleâ€negative breast cancer. International Journal of Cancer, 2020, 146, 123-136.	2.3	63
13	<scp>CEP</scp> 55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Molecular Medicine, 2018, 10, .	3.3	59
14	Indoleamine 2,3-Dioxygenase Activity Contributes to Local Immune Suppression in the Skin Expressing Human Papillomavirus Oncoprotein E7. Journal of Investigative Dermatology, 2013, 133, 2686-2694.	0.3	50
15	Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice. ELife, 2017, 6, .	2.8	50
16	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. Oncolmmunology, 2018, 7, e1445949.	2.1	46
17	CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. Oncolmmunology, 2018, 7, e1424677.	2.1	44
18	Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy. Oncolmmunology, 2019, 8, e1648171.	2.1	31

#	Article	lF	CITATION
19	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumorâ€infiltrating TÂcells. Immunology and Cell Biology, 2019, 97, 152-164.	1.0	29
20	Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade. Cancer Discovery, 2018, 8, 1066-1068.	7.7	28
21	Co-blockade of immune checkpoints and adenosine A _{2A} receptor suppresses metastasis. Oncolmmunology, 2014, 3, e958952.	2.1	22
22	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+T Cells. Cancer Research, 2016, 76, 264-274.	0.4	21
23	Interleukin-17A Promotes Arginase-1 Production and 2,4-Dinitrochlorobenzene-Induced Acute Hyperinflammation in Human Papillomavirus E7 Oncoprotein-Expressing Skin. Journal of Innate Immunity, 2015, 7, 392-404.	1.8	14
24	Blockade of PDGFRÎ ² circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltrationÂin triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 85.	3.5	13
25	Human Papillomavirus E7 Oncoprotein Transgenic Skin Develops an Enhanced Inflammatory Response to 2,4-Dinitrochlorobenzene by an Arginase-1-Dependent Mechanism. Journal of Investigative Dermatology, 2014, 134, 2438-2446.	0.3	11
26	HPV16 E7 expression in skin induces TSLP secretion, type 2 ILC infiltration and atopic dermatitisâ€like lesions. Immunology and Cell Biology, 2015, 93, 540-547.	1.0	10